The beneficial effects of an SGLT2 inhibitor, when added to standard care, on cardiovascular protection, heart failure, kidney protection, and death in the primary studies for the treatment of diabetes were impressive [11,12,13]. Here, SLC5A2 is linked to diabetes mellitus.